095700 — Genexine Balance Sheet
0.000.00%
- KR₩211bn
- KR₩255bn
- KR₩3bn
Annual balance sheet for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | ARS/A | ARS/A | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6,714 | 27,796 | 21,942 | 64,482 | 32,078 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 8,345 | 2,440 | 13,779 | 16,642 | 6,642 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20,646 | 57,274 | 52,384 | 92,160 | 46,936 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 71,856 | 111,969 | 110,932 | 114,209 | 118,938 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 596,908 | 636,865 | 388,781 | 376,587 | 345,042 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 40,217 | 59,154 | 78,933 | 54,526 | 53,992 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 61,303 | 122,937 | 116,140 | 79,965 | 83,361 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 535,605 | 513,928 | 272,641 | 296,622 | 261,681 |
Total Liabilities & Shareholders' Equity | 596,908 | 636,865 | 388,781 | 376,587 | 345,042 |
Total Common Shares Outstanding |